These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33509413)

  • 1. Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders.
    Becker SJ; Garner BR; Hartzler BJ
    J Subst Abuse Treat; 2021 Mar; 122():108210. PubMed ID: 33509413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
    Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
    J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of implementation facilitation to increase timely admission to methadone treatment.
    Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
    J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19.
    Joseph G; Torres-Lockhart K; Stein MR; Mund PA; Nahvi S
    J Subst Abuse Treat; 2021 Mar; 122():108219. PubMed ID: 33353790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 12. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
    Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
    Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.
    Bart GB; Saxon A; Fiellin DA; McNeely J; Muench JP; Shanahan CW; Huntley K; Gore-Langton RE
    Addict Sci Clin Pract; 2020 Jan; 15(1):4. PubMed ID: 31948487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont.
    Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC
    J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid use disorder: current trends and potential treatments.
    Lee YK; Gold MS; Blum K; Thanos PK; Hanna C; Fuehrlein BS
    Front Public Health; 2023; 11():1274719. PubMed ID: 38332941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
    Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
    Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial.
    Becker SJ; Murphy CM; Hartzler B; Rash CJ; Janssen T; Roosa M; Madden LM; Garner BR
    Addict Sci Clin Pract; 2021 Oct; 16(1):61. PubMed ID: 34635178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to OUD Treatment and Maintenance of Sobriety amid the COVID-19 Pandemic.
    Rahman F; Evans N; Bernhardt J
    Subst Use Misuse; 2021; 56(7):1005-1009. PubMed ID: 33754956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19.
    Frost M
    J Opioid Manag; 2020; 16(6):405-407. PubMed ID: 33428187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.